--- title: "Globus Medical paid $252.5 million for Nevro; 23 injury suits over its stimulators now share one judge" description: "Globus Medical paid $252.5 million for Nevro in April 2025, a price below the fair value of what it bought, and in August raised its 2026 profit guidance. An October 2 federal order consolidating injury claims over the same stimulators is where the case count and the bill surface first." publisher: "The Inference" section: "Health" published: 2026-10-14T21:06:10.203Z modified: 2026-10-14T21:06:10.203Z canonical: https://theinference.org/article/globus-medical-paid-252-5-million-for-nevro-23-injury-suits-over-its-stimulators-now-share-one-judge language: en keywords: "Medical Devices, Litigation, Mergers And Acquisitions" --- # Globus Medical paid $252.5 million for Nevro; 23 injury suits over its stimulators now share one judge > Globus Medical paid $252.5 million for Nevro in April 2025, a price below the fair value of what it bought, and in August raised its 2026 profit guidance. An October 2 federal order consolidating injury claims over the same stimulators is where the case count and the bill surface first. ## Twenty-three injury lawsuits land before one judge On October 2 [the U.S. Judicial Panel on Multidistrict Litigation consolidated the federal injury lawsuits](https://www.mealeys.com/mealeys/articles/2534741) over spinal cord stimulators sold by Nevro, the pain-device maker [Globus Medical](https://theinference.org/markets/companies/globus-medical) bought in April 2025, and by Globus itself, into MDL 3195 before Judge Haywood S. Gilliam Jr. of the Northern District of California, Nevro's home district [1][3]. Twenty-three cases are pending across ten districts [2]. An MDL puts related federal suits before one judge and one shared pretrial record, the place where case counts and settlement figures surface first. ## Migrating leads, painful shocks, roughly 300 claimants The complaints allege implants that migrate, break through the skin, deliver painful shocks and damage nerves, often forcing revision surgery, and that sales representatives told patients mechanical failures were programming problems [2]. Nevro opposed centralization and lost; the FDA, sued alongside Nevro in nine of the actions, filed its own response [1][3]. Plaintiffs' counsel told the panel it represents about 300 potential claimants, more than 30 of them held back only by a tolling agreement with Nevro, which pauses the deadline to sue [3]. ## The franchise behind the raised guidance Globus, the Audubon, Pennsylvania spine-implant maker, paid $5.85 a share for Nevro, $252.5 million in total, while the target was struggling under competition in spinal cord stimulation, and booked a $118.8 million bargain-purchase gain because the fair value of the assets exceeded the price [5][6]. Chief Executive Keith Pfeil calls Nevro "a clinically superior pain product" that expands the addressable market [4]. In the second quarter the base business grew 8.9%; the Nevro line fell 14.3% year over year, to roughly $81 million of sales, while its adjusted EBITDA margin swung from negative 1.4% to 22.4% [4]. Globus held 2026 revenue guidance at $3.18–3.22 billion and [raised its non-GAAP earnings-per-share guide to $4.95–5.05](https://www.benzinga.com/news/26/10/62292996/globus-medical-q2-2026-earnings-call-transcript) [4]. *Chart: **Nevro and Enabling Technologies shrank while trauma and spine grew** Bar chart of Q2 2026 year-over-year sales growth by Globus business line: Trauma up 31%, International Spine up 13.8%, U.S. Spine up 7.3%, Nevro down 14.3%, Enabling Technologies down 25.8%* *As-reported year-over-year net sales growth by business, Q2 2026, per Globus Medical's Q2 earnings call. Trauma and spine grew; the two lines in transition did not. [4]* *Chart: **Revenue has topped $745 million in every quarter since the Nevro deal closed** Line chart of Globus Medical quarterly net revenue, Q3 2023 to Q2 2026: $383.6 million rising to $789.6 million, stepping up in Q2 2025 when the Nevro deal closed* *Globus Medical quarterly net revenue as reported in its SEC filings, Q3 2023 through Q2 2026, in millions of dollars. Nevro was acquired in April 2025, inside Q2 2025. [9]* ## The filing that does not name the cases The securities record is thinner than the docket. The legal-proceedings note in Globus's [Q2 10-Q, filed with the SEC on August 6](https://www.sec.gov/Archives/edgar/data/1237831/000162828026054450/gmed-20260630.htm), itemizes three matters: the Moskowitz and 4WEB patent fights, and the Pimenta contract case, where a $28.7 million jury verdict became a $43.1 million accrual [5]. The stimulator cases are not itemized and carry no disclosed reserve, so the only numbers live in the MDL docket [3][5]. The fair view runs the other way first. Twenty-three cases are small against a company holding $840.5 million in cash and marketable securities [4]. Management says Nevro sales held flat from the first quarter, with trial volumes returning to historical levels late in the fourth quarter [4]. ## Each case opens with a fight over federal preemption The legal terrain is not a one-way street either. Every stimulator case now opens with a threshold fight over federal preemption, whether FDA approval bars the state-law claims, and the answer depends on which circuit hears the case [3]. MDL 3195 sits in the Ninth Circuit, where plaintiffs must show Nevro deviated from a specific FDA premarket-approval requirement, and at least one Nevro case has already survived a preemption challenge [3]. ## Two records that will price the risk Globus is showing its FDA-cleared SCRIPT patient-specific spine implants at the North American Spine Society's annual meeting in San Antonio this week; the meeting runs October 14–17 [8]. Three weeks later, on November 5, the company reports third-quarter results [7]. Two records will price the Nevro risk before any balance sheet does: the trial volumes management promised by year end, and the MDL 3195 docket, where the roughly 300 potential claimants either file or do not [3][4]. Globus paid less than Nevro's parts were worth; the MDL docket is where the cost of the injury claims gets counted first [3][5]. ## Takeaway Globus Medical bought Nevro for less than its assets were worth and raised its 2026 profit guide, but 23 injury suits over the same stimulators now sit before one judge, where roughly 300 potential claimants will price the risk before any balance sheet does. ## Sources 1. [Mealey's, JPMDL Agrees To Centralize Nevro, Globus Medical Spinal Cord Stimulator Injury Cases, 6 October 2026](https://www.mealeys.com/mealeys/articles/2534741) 2. [Becker's Spine Review, Abbott, Nevro spinal cord stimulator lawsuits sent to 2 federal courts, 6 October 2026](https://www.beckersspine.com/spinal-tech/abbott-nevro-spinal-cord-stimulator-lawsuits-sent-to-2-federal-courts/) 3. [Marin & Murphy via JD Supra, Spinal Cord Stimulator MDLs: Three Proceedings, Two Circuits, and the Preemption Split the JPML Just Built, 8 October 2026](https://www.jdsupra.com/legalnews/spinal-cord-stimulator-mdls-three-6681559/) 4. [Benzinga, Globus Medical Q2 2026 Earnings Call Transcript, collected 13 October 2026](https://www.benzinga.com/news/26/10/62292996/globus-medical-q2-2026-earnings-call-transcript) 5. [Globus Medical Form 10-Q for the quarter ended 30 June 2026, filed with the SEC 6 August 2026](https://www.sec.gov/Archives/edgar/data/1237831/000162828026054450/gmed-20260630.htm) 6. [MD+DI (Informa), Globus Financials Strong in Midst of Nuvasive, Nevro Integration, 25 February 2026](https://www.mddionline.com/neurological/globus-financials-strong-in-midst-of-nuvasive-nevro-integration) 7. [Pluang, Globus Medical to release Q3 2026 earnings on 5 November, 14 October 2026](https://pluang.com/en/news-feed/globus-medical-jadwalkan-rilis-laporan-keuangan-kuartal-iii) 8. [GlobeNewswire via Yahoo Finance, Globus Medical to Showcase SCRIPT Patient-Specific Implants at NASS 2026, 14 October 2026](https://finance.yahoo.com/healthcare/articles/globus-medical-showcase-script-patient-120000960.html) 9. [Globus Medical, quarterly figures from its SEC filings, retrieved 14 October 2026](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001237831) --- Globus Medical paid $252.5 million for Nevro; 23 injury suits over its stimulators now share one judge — The Inference. Canonical: https://theinference.org/article/globus-medical-paid-252-5-million-for-nevro-23-injury-suits-over-its-stimulators-now-share-one-judge